|By PR Newswire||
|December 10, 2013 07:00 AM EST||
CAMBRIDGE, England, December 10, 2013 /PRNewswire/ --
Sphere Fluidics Limited has developed unique technology for single cell analysis and characterization and provides proprietary products and novel services for this rapidly-growing market. This enabling approach can find rare variants in large cell populations and Sphere Fluidics has patented novel Cyto-Mine™ technology that permits up to one billion assays per biochip per day. Their technology provides significant operational benefits for biopharmaceutical discovery and development, cancer variation studies, analysis of antibiotic-resistance mutants and identification of novel enzymes and synthetic biology pathways. Sphere Fluidics completed a funding round of circa $3 million earlier this year and has now moved into a larger facility nearby to Cambridge (UK) to enable growth.
The firm has used the funding to recruit new technical staff, a Commercial Director and has now hired a new R&D Director (Dr Marian Rehak). Dr Rehak previously held Senior R&D positions with Unipath and DxTech, has more than 20 years in Life Sciences R&D and has been hired to help grow the business. "I am excited to be joining the Sphere Fluidics team at this crucial time. We will now not only provide enabling R&D Services, but also develop and launch new Products (e.g. novel instrumentation systems) for single cell analysis," says Dr. Rehak. "Our systems will not only enabling for discovery and development of diverse biopharmaceuticals, but has also created excitement in the emerging field of synthetic biology," he states.
Sphere Fluidics now has almost 120 different, international organizations buying their products. These include leading pharmaceutical companies, Life Sciences biotechsa nd well-known research institutions. The Company has also recently signed several, new collaborative R&D agreements with a number of Blue Chip pharmaceutical companies in an acceleration of their Service business.
"The Company has recently completed comprehensive, market analysis to ensure that our new instrumentation systems were defined by the customer base and are targeted into major global markets," says Dr Frank F. Craig (CEO). "Dr Rehak is part of our plan to rapidly grow the R&D function and our select markets. We welcome him into the Company and look forward to his contribution to our continued success."
Sphere Fluidics Limited.
Contact Dr Frank F. Craig on:
E-mail: [email protected]
SOURCE Sphere Fluidics Limited